Document is current
Any future updates will be listed below
-
Authors
Enzan, Nobuyuki https://orcid.org/0000-0002-3899-4405
Miyazawa, Kazuo
Koyama, Satoshi https://orcid.org/0000-0002-9286-0360
Kurosawa, Ryo
Ieki, Hirotaka https://orcid.org/0000-0002-6252-6134
Yoshida, Hiroki
Takechi, Fumie
Fukuyama, Masashi
Osako, Ryosuke
Tomizuka, Kohei
Liu, Xiaoxi
Ozaki, Kouichi https://orcid.org/0000-0003-0028-1570
Onouchi, Yoshihiro https://orcid.org/0000-0003-1267-5913
,
Matsuda, Koichi https://orcid.org/0000-0001-7292-2686
Momozawa, Yukihide https://orcid.org/0000-0001-5638-3504
Aburatani, Hiroyuki https://orcid.org/0000-0003-0438-1544
Kamatani, Yoichiro https://orcid.org/0000-0001-8748-5597
Yamaguchi, Takanori https://orcid.org/0000-0002-0613-8591
Akazawa, Hiroshi https://orcid.org/0000-0002-3574-9607
Node, Koichi https://orcid.org/0000-0002-2534-0939
Ellinor, Patrick T. https://orcid.org/0000-0002-2067-0533
Levin, Michael G. https://orcid.org/0000-0002-9937-9932
Damrauer, Scott M. https://orcid.org/0000-0001-8009-1632
Voight, Benjamin F. https://orcid.org/0000-0002-6205-9994
Joseph, Jacob https://orcid.org/0000-0002-7279-4896
Sun, Yan V. https://orcid.org/0000-0002-2838-1824
Terao, Chikashi https://orcid.org/0000-0002-6452-4095
Ninomiya, Toshiharu https://orcid.org/0000-0003-1345-9032
Komuro, Issei
Ito, Kaoru https://orcid.org/0000-0003-1843-773X
- License Information
-
More Information
Article History
Received: 24 November 2024
Accepted: 23 September 2025
First Online: 3 November 2025
Competing interests
: S.D. reports in kind research support from Novo Nordisk and Amgen, and personal consulting fees from Tourmaline Bio. The other authors declare no competing interests associated with this manuscript. Dr. Ellinor receives sponsored research support from Bayer AG, Bristol Myers Squibb, Pfizer and Novo Nordisk; he has also served on advisory boards or consulted for Bayer AG.
